<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02028767</url>
  </required_header>
  <id_info>
    <org_study_id>1276.24</org_study_id>
    <nct_id>NCT02028767</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets</brief_title>
  <official_title>Bioequivalence of Empagliflozin/Metformin (12.5mg/500mg) Fixed Dose Combination Tablets Compared to Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open Label, Randomised, Single Dose, Two Period, Two Sequence Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The trial is being conducted to establish the bioequivalence of emp/met (12.5mg/500mg) fixed
      dose combination tablets compared to tablets administered together in healthy male and female
      volunteers under fed conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (0-tz) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>AUC (0-tz) (area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Maximum Measured Concentration of Metformin in Plasma)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>Cmax (maximum measured concentration of metformin in plasma)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC (0-infinity) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>AUC (0-infinity) (Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fixed Dose Combination (FDC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12.5 mg Empagliflozin / 500mg metformin fixed dose combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Separate tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Empagliflozin and Metformin tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 2.5 mg</intervention_name>
    <description>Empagliflozin 2.5 mg tablet</description>
    <arm_group_label>Separate tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 mg</intervention_name>
    <description>Empagliflozin 10 mg tablet</description>
    <arm_group_label>Separate tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 500 mg</intervention_name>
    <description>Metformin 500 mg tablet</description>
    <arm_group_label>Separate tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin/Metformin FDC</intervention_name>
    <description>12.5 mg Empagliflozin / 500 mg Metformin</description>
    <arm_group_label>Fixed Dose Combination (FDC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males or females according to the investigator's assessment, as based on the
             following criteria: a complete medical history including a physical examination, vital
             signs (BP, PR), 12-lead ECG and clinical laboratory tests.

          2. Age 18 to 50 years (inclusive)

          3. BMI 18.5 to 29.9 kg/m2 (inclusive)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and local legislation.

        Exclusion criteria:

          1. Any finding in the medical examination (Including blood pressure [BP], pulse rate
             [PR], or electrocardiogram [ECG]) deviating from normal and judged clinically relevant
             by the investigator.

          2. Any evidence of a concomitant disease judged clinically relevant by the investigator.

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders.

          4. Surgery of the gastrointestinal tract that could interfere with kinetics of the study
             drug(s)

          5. Diseases of the central nervous system (such as epilepsy), other neurological
             disorders or psychiatric disorders.

          6. History of relevant orthostatic hypotension, fainting spells, or blackouts.

          7. Chronic or relevant acute infections

          8. History of relevant allergy/hypersensitivity (including allergy to the trial
             medication or it's excipients)

          9. Intake of drugs with a long half-life (&gt;24 hours) within 30 days or less than 10
             half-lives of the respective drug prior to administration of trial medication.

         10. Within 14 days prior to the administration of trial medication, use of drugs that
             might reasonably influence the results of the trial, based on current knowledge

         11. Participation in another trial with investigational drug administration within 60 days
             prior to administration of trial medication.

         12. Smoker (has used tobacco or nicotine-containing products within 6 months prior to
             administration of trial medication)

         13. Inability to refrain from smoking on specified trial days

         14. Alcohol abuse (consumption of more than 20g/day in females and 30g/day in males or &gt; 7
             alcohol-containing drinks per week)

         15. Drug abuse or positive drug screen

         16. Blood donation (more than 100 ml wihtin 30 days prior to administration of trial
             medication or intended during the trial)

         17. Intention to perform excessive physical activities within one week prior to
             administration of trial medication or during the trial

         18. Inability to comply with dietary regimen of trial site

         19. Subject is assessed by the investigator as unsuitable for inclusion, for instance,
             because considered not able to understand and comply with study requirements, or has a
             condition that would not allow safe participation in the study.

             For female subjects:

         20. Positive pregnancy test, pregnancy or plans to become pregnant within 30 days after
             study completion.

         21. No adequate contraception during the study and until 1 month after study completion,
             i.e. not any of the following: implants, injectables, combined oral contraceptives,
             IUD (intrauterine device), sexual abstinence for at least 1 month prior to enrolment,
             vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or
             surgical sterilisation (including hysterectomy). Females, who do not have a
             vasectomised partner, are not sexually abstinent, surgically sterile, or post
             menopausal will be asked to use an additional barrier method (e.g. condom, diaphragm
             with spermicide). Post-menopausal is defined as at least 1 year of spontaneous
             amenorrhea and deemed post menopausal by a physician based on screening clinical
             laboratory tests (follicle stimulating hormone and luteinizing hormone).

         22. Lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1276.24.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2014</study_first_submitted>
  <study_first_submitted_qc>January 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2014</study_first_posted>
  <results_first_submitted>June 26, 2015</results_first_submitted>
  <results_first_submitted_qc>June 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 24, 2015</results_first_posted>
  <last_update_submitted>June 26, 2015</last_update_submitted>
  <last_update_submitted_qc>June 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fixed Dose Combination (FDC) First, Then Separate Tablets</title>
          <description>Empagliflozin / Metformin FDC: 12.5 mg Empagliflozin / 500 mg Metformin first,
then free combination of Empagliflozin 2.5 mg tablet, Empagliflozin 10 mg tablet and Metformin 500 mg tablet
Both medications were administered oral with 240 mL water after intake of a high-fat, high-calorie meal.</description>
        </group>
        <group group_id="P2">
          <title>Separate Tablets First, Then Fixed Dose Combination (FDC)</title>
          <description>free combination of Empagliflozin 2.5 mg tablet, Empagliflozin 10 mg tablet and Metformin 500 mg tablet first,
then Empagliflozin / Metformin FDC: 12.5 mg Empagliflozin / 500 mg Metformin
Both medications were administered oral with 240 mL water after intake of a high-fat, high-calorie meal.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non compliant with protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason other than those specified above</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS): includes all subjects who were dispensed study medication and were documented to have received at least 1 dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Fixed Dose Combination vs. Separate Tablets</title>
          <description>12.5 mg Empagliflozin / 500mg metformin fixed dose combination vs. free combination of 2.5 mg tablet Empagliflozin, 10 mg tablet Empagliflozin and 500 mg tablet Metformin</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.1" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-tz) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point)</title>
        <description>AUC (0-tz) (area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point)</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>Pharmacokinetic set (PKS): includes all subjects of the TS who provided at least 1 observation for at least 1 primary pharmacokinetic endpoint, and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Fixed Dose Combination (FDC)</title>
            <description>12.5 mg Empagliflozin / 500mg metformin fixed dose combination
Empagliflozin / Metformin FDC: 12.5 mg Empagliflozin / 500 mg Metformin</description>
          </group>
          <group group_id="O2">
            <title>Separate Tablets</title>
            <description>Empagliflozin and Metformin tablets
Empagliflozin 2.5 mg: Empagliflozin 2.5 mg tablet
Empagliflozin 10 mg: Empagliflozin 10 mg tablet
Metformin 500 mg: Metformin 500 mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-tz) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point)</title>
          <description>AUC (0-tz) (area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point)</description>
          <population>Pharmacokinetic set (PKS): includes all subjects of the TS who provided at least 1 observation for at least 1 primary pharmacokinetic endpoint, and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6260" spread="20.4"/>
                    <measurement group_id="O2" value="6360" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence test</non_inferiority_desc>
            <p_value>0.0000</p_value>
            <p_value_desc>The p-value relates to the null hypothesis of non-equivalence.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>98.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.024</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.662</ci_lower_limit>
            <ci_upper_limit>102.639</ci_upper_limit>
            <estimate_desc>The geometric mean ratio is the exponential of the estimated mean difference on the log-scale between 'FDC' and 'Separate tablets'.
ANOVA on the log scale: sequence, period and treatment as fixed effects; subjects within sequences as random effect</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis with fixed effects for all terms</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence test</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value relates to the null hypothesis of non-equivalence.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>98.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.024</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.783</ci_lower_limit>
            <ci_upper_limit>102.796</ci_upper_limit>
            <estimate_desc>The geometric mean ratio is the exponential of the estimated mean difference on the log-scale between 'FDC' and 'Separate tablets'.
ANOVA on the log-scale: sequence, subjects within sequences, period and treatment as fixed effects</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Measured Concentration of Metformin in Plasma)</title>
        <description>Cmax (maximum measured concentration of metformin in plasma)</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>PKS: includes all subjects of the TS who provided at least 1 observation for at least 1 primary pharmacokinetic endpoint, and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Fixed Dose Combination (FDC)</title>
            <description>12.5 mg Empagliflozin / 500mg metformin fixed dose combination
Empagliflozin / Metformin FDC: 12.5 mg Empagliflozin / 500 mg Metformin</description>
          </group>
          <group group_id="O2">
            <title>Separate Tablets</title>
            <description>Empagliflozin and Metformin tablets
Empagliflozin 2.5 mg: Empagliflozin 2.5 mg tablet
Empagliflozin 10 mg: Empagliflozin 10 mg tablet
Metformin 500 mg: Metformin 500 mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Measured Concentration of Metformin in Plasma)</title>
          <description>Cmax (maximum measured concentration of metformin in plasma)</description>
          <population>PKS: includes all subjects of the TS who provided at least 1 observation for at least 1 primary pharmacokinetic endpoint, and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="746" spread="21.3"/>
                    <measurement group_id="O2" value="754" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence test</non_inferiority_desc>
            <p_value>0.0000</p_value>
            <p_value_desc>The p-value relates to the null hypothesis of non-equivalence.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>98.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.019</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.856</ci_lower_limit>
            <ci_upper_limit>102.107</ci_upper_limit>
            <estimate_desc>The geometric mean ratio is the exponential of the estimated mean difference on the log-scale between 'FDC' and 'Separate tablets'.
ANOVA on the log-scale: sequence, period and treatment as fixed effects; subjects within sequences as random effect</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis with fixed effects for all terms</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence test</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value relates to the null hypothesis of non-equivalence.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>98.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.019</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.877</ci_lower_limit>
            <ci_upper_limit>102.150</ci_upper_limit>
            <estimate_desc>The geometric mean ratio is the exponential of the estimated mean difference on the log-scale between 'FDC' and 'Separate tablets'.
ANOVA on the log-scale: sequence, subjects within sequences, period and treatment as fixed effects</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0-infinity) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)</title>
        <description>AUC (0-infinity) (Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity)</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>PKS: includes all subjects of the TS who provided at least 1 observation for at least 1 primary pharmacokinetic endpoint, and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Fixed Dose Combination (FDC)</title>
            <description>12.5 mg Empagliflozin / 500mg metformin fixed dose combination
Empagliflozin / Metformin FDC: 12.5 mg Empagliflozin / 500 mg Metformin</description>
          </group>
          <group group_id="O2">
            <title>Separate Tablets</title>
            <description>Empagliflozin and Metformin tablets
Empagliflozin 2.5 mg: Empagliflozin 2.5 mg tablet
Empagliflozin 10 mg: Empagliflozin 10 mg tablet
Metformin 500 mg: Metformin 500 mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-infinity) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)</title>
          <description>AUC (0-infinity) (Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity)</description>
          <population>PKS: includes all subjects of the TS who provided at least 1 observation for at least 1 primary pharmacokinetic endpoint, and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6410" spread="20.9"/>
                    <measurement group_id="O2" value="6520" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence test</non_inferiority_desc>
            <p_value>0.0000</p_value>
            <p_value_desc>The p-value relates to the null hypothesis of non-equivalence.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>98.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.023</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.549</ci_lower_limit>
            <ci_upper_limit>102.156</ci_upper_limit>
            <estimate_desc>The geometric mean ratio is the exponential of the estimated mean difference on the log-scale between 'FDC' and 'Separate tablets'.
ANOVA on the log-scale: sequence, period and treatment as fixed effects; subjects within sequences as random effect</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis with fixed effects for all terms</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence test</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>The p-value relates to the null hypothesis of non-equivalence.</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>98.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.023</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.603</ci_lower_limit>
            <ci_upper_limit>102.252</ci_upper_limit>
            <estimate_desc>The geometric mean ratio is the exponential of the estimated mean difference on the log-scale between 'FDC' and 'Separate tablets'.
ANOVA on the log-scale: sequence, subjects within sequences, period and treatment as fixed effects</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first trial medication intake until next intake or the day after the end-of-trial visit, 16 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fixed Dose Combination (FDC)</title>
          <description>12.5 mg Empagliflozin / 500mg metformin fixed dose combination
Empagliflozin / Metformin FDC: 12.5 mg Empagliflozin / 500 mg Metformin</description>
        </group>
        <group group_id="E2">
          <title>Separate Tablets</title>
          <description>Empagliflozin and Metformin tablets
Empagliflozin 2.5 mg: Empagliflozin 2.5 mg tablet
Empagliflozin 10 mg: Empagliflozin 10 mg tablet
Metformin 500 mg: Metformin 500 mg tablet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

